{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-16T02:45:01.983988+00:00","company":{"ticker":"NEUP","cik":1191070,"company_name":"Neuphoria Therapeutics Inc."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"ma_counterparty":[{"display_name":"Neuphoria Therapeutics Inc.","detail":"change_of_control","count":1,"first_seen":"2024-12-23T23:59:59+00:00","last_seen":"2024-12-23T23:59:59+00:00","evidence_fact_ids":[102473]}]},"facts":[{"fact_type":"exchange_compliance_notice","fact_key":"df3eb2f3e2b01c226b876714f3a8e4f719980a82","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-12-18T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"shareholders","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-12-18","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5620(a)"],"rules_cited_in_text":true},"claim":"Neuphoria Therapeutics Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5620(a)).","evidence_excerpt":"ompany was not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold a qualified annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-123289","anchor_url":"https://secwatch.observer/filing/0001213900-25-123289#claim-df3eb2f3e2b01c226b876714f3a8e4f719980a82","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025123289/0001213900-25-123289-index.htm"},{"fact_type":"equity_issuance","fact_key":"dc096336b3c0c5e4ba95da05cb04ec3d9307bcb5","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-10-27T23:59:59+00:00","payload":{"action":"rights_modification","consideration_text":null,"effective_date":"2025-10-27","item_codes_triggered":["3.03"],"purchaser":null,"security_type":"common_stock","shares_text":null},"claim":"Neuphoria Therapeutics Inc. issued common stock.","evidence_excerpt":"the Board declared a dividend of one preferred share purchase right for each outstanding share of the Company’s common stock as of the close of business on October 27, 2025, the record date","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-102607","anchor_url":"https://secwatch.observer/filing/0001213900-25-102607#claim-dc096336b3c0c5e4ba95da05cb04ec3d9307bcb5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/0001213900-25-102607-index.htm"},{"fact_type":"governance_change","fact_key":"5f80f01626bed1c1c430f0b7a4c52495b512334c","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-10-27T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-10-27","item_codes_triggered":["5.03"],"summary_text":"Adoption of Certificate of Designations establishing Preferred Shares and their rights"},"claim":"Neuphoria Therapeutics Inc.: Adoption of Certificate of Designations establishing Preferred Shares and their rights (effective 2025-10-27).","evidence_excerpt":"Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the adoption of the Rights Agreement referenced in Item 1.01 above, the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on October 27, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-102607","anchor_url":"https://secwatch.observer/filing/0001213900-25-102607#claim-5f80f01626bed1c1c430f0b7a4c52495b512334c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/0001213900-25-102607-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"82826ecdc82d41142ae2ca9bd097b4e009e601d5","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-09-16T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-12-29","deficiency_type":"shareholders","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year end","notice_date":"2025-09-10","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5620(a)","reported_value":null,"rule_numbers":["5620(a)"],"rules_cited_in_text":true},"claim":"Neuphoria Therapeutics Inc. received a nasdaq extension granted notice regarding shareholders (rules 5620(a)).","evidence_excerpt":"September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension\nof 180 calendar days (the “ Compliance Period ”) from the end of the Company’s fiscal year, or until December\n29, 2025, to regain compliance with the Listing Rule. To this end, the Company\nintends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy\nstatement and notice of shareholder meeting related to the Company’s 2025 annual general shareholder meeting, and further intends\nto hold such","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-087950","anchor_url":"https://secwatch.observer/filing/0001213900-25-087950#claim-82826ecdc82d41142ae2ca9bd097b4e009e601d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025087950/0001213900-25-087950-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"bcb2eea891b943209c8e8653a504b30caa0b300f","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-07-18T23:59:59+00:00","payload":{"company_response":"company intends to submit a plan and hold 2025 annual meeting in November 2025","compliance_status":"plan_due","cure_deadline":"2025-12-29","deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"annual meeting within twelve months of fiscal year end","notice_date":"2025-07-18","notice_type":"deficiency_notice","plan_due_date":"2025-09-01","raw_rule_text":"Nasdaq Listing Rule 5620(a)","reported_value":"no annual meeting held by June 30, 2025","rule_numbers":["5620(a)"],"rules_cited_in_text":true},"claim":"Neuphoria Therapeutics Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).","evidence_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-065723","anchor_url":"https://secwatch.observer/filing/0001213900-25-065723#claim-bcb2eea891b943209c8e8653a504b30caa0b300f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm"},{"fact_type":"governance_change","fact_key":"da1da50faff809b9708bfea9a3b0fdd32b851001","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2024-12-23T23:59:59+00:00","payload":{"change_type":"code_of_ethics","effective_date":null,"item_codes_triggered":["5.05"],"summary_text":"Code of Conduct adopted, applies to all directors, officers and employees"},"claim":"Neuphoria Therapeutics Inc.: Code of Conduct adopted, applies to all directors, officers and employees.","evidence_excerpt":"Neuphoria has adopted a Code of Conduct (the “Code”), which applies to all directors, officers and employees","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-112016","anchor_url":"https://secwatch.observer/filing/0001213900-24-112016#claim-da1da50faff809b9708bfea9a3b0fdd32b851001","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm"},{"fact_type":"governance_change","fact_key":"177adc196fdca1a965676b9ff0a5bb0aaa6ef0c8","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2024-12-23T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Bylaws adopted in connection with redomiciliation"},"claim":"Neuphoria Therapeutics Inc.: Bylaws adopted in connection with redomiciliation.","evidence_excerpt":"rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation and its bylaws","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-112016","anchor_url":"https://secwatch.observer/filing/0001213900-24-112016#claim-177adc196fdca1a965676b9ff0a5bb0aaa6ef0c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm"},{"fact_type":"governance_change","fact_key":"50f23270c022e1eb62679dd9df7ce412ff632daa","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2024-12-23T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Amended and Restated Certificate of Incorporation adopted in connection with redomiciliation"},"claim":"Neuphoria Therapeutics Inc.: Amended and Restated Certificate of Incorporation adopted in connection with redomiciliation.","evidence_excerpt":"rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-112016","anchor_url":"https://secwatch.observer/filing/0001213900-24-112016#claim-50f23270c022e1eb62679dd9df7ce412ff632daa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm"},{"fact_type":"ma_transaction","fact_key":"08f5192d677edf536b4799768154032636c1b91a","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2024-12-23T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2024-12-23","consideration_text":null,"counterparty":"Neuphoria Therapeutics Inc.","effective_date":"2024-12-23","item_codes_triggered":["5.01"]},"claim":"Neuphoria Therapeutics Inc. underwent a change of control involving Neuphoria Therapeutics Inc. (closed 2024-12-23).","evidence_excerpt":"On December 23, 2024 US time (“Effective Date”), the redomiciliation (“Redomiciliation”) of Bionomics Limited, an Australian corporation (“Bionomics”), was implemented under Australian law in accordance with a Scheme Implementation Agreement (as amended) between Bionomics and Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-112016","anchor_url":"https://secwatch.observer/filing/0001213900-24-112016#claim-08f5192d677edf536b4799768154032636c1b91a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm"},{"fact_type":"executive_change","fact_key":"9db0dd5acb","cik":1191070,"ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2024-10-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-09","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Aaron Weaver resigned as Director at Neuphoria Therapeutics Inc..","evidence_excerpt":"On October 9, 2024, Mr. Aaron Weaver, a member of the Board of Directors of Bionomics Limited (the “Company”), provided the Company’s board with notice that he was resigning from the Board of Directors, effective October 9, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-086918","anchor_url":"https://secwatch.observer/filing/0001213900-24-086918#claim-9db0dd5acb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024086918/0001213900-24-086918-index.htm"}]}